First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

The phase I dose escalation will be conducted utilizing the standard 3+3 dose escalation method. Pharmacokinetic (PK) data will be obtained for MBF-362.

The phase I dose expansion will consist of 1 group including solid tumors cancer patients. Pharmacodynamic (PD) data will be obtained for potential biomarker analysis with pre-treatment and on-treatment tumor biopsies.

Phase I Dose Escalation (3+3 Design): the MTD will be defined as the highest dose level at which less than 2 out of 6 patients (<33%) experience DLT in Cycle 1 (first 28 days).

Phase I Safety Expansion once RP2D has been declared for MBF-362 using the standard 3+3 design, up to 20 additional solid tumor cancer patients may be treated at the RP2D to further explore safety and tolerability of the selected MBF-362 dose.

Patients must have histologically or cytologically confirmed cancer with at least one measurable lesion, with adequate organ and marrow function, and with ECOG performance status of 0-1. Eligible patients must have received at least one prior line of therapy for their disease.

Inclusion criteria

• These criteria are similarly applicable to patients enrolled to the phase I dose escalation and to the phase IB dose expansion portions of the trial.

• Advanced/metastatic histologically confirmed solid tumor. All types of solid tumors are allowed in the study
• At least 1 measurable lesion per Response Evaluation Criteria in solid tumor (RECIST 1.1).
• Patients who have progressed to the standard therapy and have no approved optional therapy available.
• ECOG performance status of 0/1
• Age greater than 18 years (inclusive).
• Adequate bone marrow, renal and hepatic function
• Able and willing to give valid written consent for available archival tumor samples (mandatory) and tumor biopsies before and during protocol (immune)therapy (optional in escalation phase and mandatory in expansion phase).
• Prior immunotherapy is also allowed.

Exclusion criteria

• These criteria are similarly applicable to patients enrolled to the phase I dose escalation and to the phase IB dose expansion portions of the trial.

• Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lives prior to starting on treatment.
• Symptomatic and/or untreated Brain Metastases
• Pregnancy or breast feeding
• Serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the patient's ability to receive study treatment.
• Concurrent use of other anticancer approved or investigational agents is not allowed.
• Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
• Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol.
• Patients receiving oral or systemic steroids 2 weeks prior to dosing with MBF-362
• Patients receiving >4 doses of anti-inflammatory (NSAID) treatments, modulators of the COX-2 pathway or aspirin 1 week prior to dosing with MBF-362
• Patients with a history of gastric/duodenal ulcers, colitis and/or gastrointestinal bleeding, severe gastrointestinal adverse reactions
• Patients with a history of anaphylaxis, uncontrolled asthma or allergy/hypersensitivity/intolerance to NSAIDs, COX-2 inhibitors or aspirin.